Cargando…
CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results
BACKGROUND: Patients with refractory/relapsed (r/r) acute B lymphocytic leukemia (B-ALL) can achieve complete response (CR) after chimeric antigen receptor T-cell (CAR-T) therapy, but recurrence occurs in the short term. To reduce recurrence and improve survival, CAR-T therapy followed by transplant...
Autores principales: | Li, Zhihui, Yang, Keyan, Song, Yanzhi, Zhao, Yongqiang, Wu, Fan, Wen, Xiaopei, Li, Jing, Wang, Xianxuan, Xu, Teng, Zheng, Xiaoyu, Zheng, Qinglong, Wu, Tong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846489/ https://www.ncbi.nlm.nih.gov/pubmed/36686744 http://dx.doi.org/10.3389/fonc.2022.1048296 |
Ejemplares similares
-
Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report
por: Wang, Dongmei, et al.
Publicado: (2018) -
Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report
por: Li, Zhihui, et al.
Publicado: (2022) -
Low Toxicity and Favorable Overall Survival in Relapsed/Refractory B-ALL following CAR T cells and CD34-selected T Cell Depleted Allogeneic Hematopoietic Cell Transplant.
por: Fabrizio, Vanessa A., et al.
Publicado: (2020) -
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023) -
PB2427: THE RISK FACTORS ON THE SEVERITY OF SARS-COV2 OMICRON VARIANT INFECTION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIEITC STEM CELL TRANSPLANTATION
por: LI, Zhihui, et al.
Publicado: (2023)